Tenth generic of thrombopoietin drug Revolade to enter Russian market - GxP News

Tenth generic of thrombopoietin drug Revolade to enter Russian market  GxP News

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytop...

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder  Novartis

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe a...

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia  GSK

Long-term safety data for Revolade in adults with chronic ITP - European Pharmaceutical Review

Long-term safety data for Revolade in adults with chronic ITP  European Pharmaceutical Review

Generic Medicine OKd by Europe for Thrombocytopenia With HCV - Medscape

Generic Medicine OKd by Europe for Thrombocytopenia With HCV  Medscape

Novartis' Revolade gets expanded coverage for immune thrombocytopenia patients - koreabiomed.com

Novartis' Revolade gets expanded coverage for immune thrombocytopenia patients  koreabiomed.com

Type Analysis - Market.us

Type Analysis  Market.us

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocyto...

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)  Novartis

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia - The New England Journal of Med...

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia  The New England Journal of Medicine

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Ph...

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) | Journal of Clinical Oncology  ASCO Publications

NICE thumbs-up for Revolade - Pharmafile

NICE thumbs-up for Revolade  Pharmafile

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Re...

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade  GSK

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with s...

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia  Novartis

Novartis’ Revolade proved effective for seniors - koreabiomed.com

Novartis’ Revolade proved effective for seniors  koreabiomed.com

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other...

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies  Novartis

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia - koreabiomed.com

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia  koreabiomed.com

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designati...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication  Novartis

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplasti...

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder  Novartis

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year an...

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP  Novartis

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment i...

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia  Novartis

Novartis bags EU approvals for three ex-GSK drugs - PMLiVE

Novartis bags EU approvals for three ex-GSK drugs  PMLiVE

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic sy...

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes  GSK

Novartis' patent on eltrombopag olamine upheld by Delhi High Court - The Pharma Letter

Novartis' patent on eltrombopag olamine upheld by Delhi High Court  The Pharma Letter

GSK guilty of off-label promotion - Pharmafile

GSK guilty of off-label promotion  Pharmafile

New hope for ITP patients dashed by high drug cost - CBC

New hope for ITP patients dashed by high drug cost  CBC

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) - Nov...

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  Novartis

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura - The New England Jo...

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura  The New England Journal of Medicine

GSK’s Promacta extends US licence - Pharmafile

GSK’s Promacta extends US licence  Pharmafile

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Rev...

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis  Frontiers

Promacta receives Breakthrough Therapy designation for SAA - European Pharmaceutical Review

Promacta receives Breakthrough Therapy designation for SAA  European Pharmaceutical Review

FDA expands use of eltrombopag - MDEdge

FDA expands use of eltrombopag  MDEdge

GlaxoSmithKline guilty of promoting blood drug for unlicensed use | GSK - The Guardian

GlaxoSmithKline guilty of promoting blood drug for unlicensed use | GSK  The Guardian

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns - AboutLawsuits.com

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns  AboutLawsuits.com

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17 - Market Realist

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17  Market Realist